Analyst Price Targets — EOLS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 4, 2026 12:32 pm | Uy Ear | Mizuho Securities | $15.00 | $4.70 | TheFly | Evolus price target lowered to $15 from $19 at Mizuho |
| January 22, 2026 12:15 pm | — | BTIG | $13.00 | $4.90 | TheFly | Evolus price target lowered to $13 from $18 at BTIG |
| January 13, 2026 12:12 pm | Annabel Samimy | Stifel Nicolaus | $17.00 | $5.77 | TheFly | Evolus price target lowered to $17 from $20 at Stifel |
| December 1, 2025 9:34 pm | Vamil Divan | Mizuho Securities | $19.00 | $6.82 | StreetInsider | Evolus (EOLS) PT Lowered to $19 at Mizuho |
| October 3, 2024 6:57 am | Douglas Tsao | H.C. Wainwright | $27.00 | $17.05 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Evolus (EOLS) |
| September 13, 2024 5:26 am | Balaji Prasad | Barclays | $20.00 | $16.46 | TheFly | Evolus price target raised to $20 from $16 at Barclays |
| September 13, 2024 5:11 am | Vamil Divan | Mizuho Securities | $25.00 | $16.46 | StreetInsider | Evolus (EOLS) PT Raised to $25 at Mizuho |
| January 29, 2024 3:32 am | Balaji Prasad | Barclays | $16.00 | $13.47 | StreetInsider | Barclays Upgrades Evolus (EOLS) to Overweight |
Latest News for EOLS
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during April 2026 to July 2026 of an aggregate of 115,000 restricted stock units (RSUs) of the company's common stock to 38 newly hired non-executive employees of the company. The awards were approved by the compensation…
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and commercialize Profhilo® in the United States. Profhilo® is the market-leading injectable…
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Jefferies Global Healthcare Conference in New York City. The fireside chat will take place on Thursday, June 4th, 2026, at 12:50 PM…
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the commercial launch of Estyme® (pronounced “esteem”), its injectable hyaluronic acid (HA) gel collection in Europe, is scheduled for May 16th, marking the company's entry into the international dermal filler market. The…
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EOLS.
U.S. House Trading
No House trades found for EOLS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.